Corcept Therapeutics Incorporated (CORT)
NEUTRALFundamental
58
Kurs
$123.06
Marktkapitalisierung
$13.04B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$831M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$55M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$142M
Gesamtes Eigenkapital
$648M
Gesamtverbindlichkeiten
$189M
Current Ratio
2.86
Zinsdeckungsgrad
-
Schulden/EBITDA
0.21
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$99.79
Aktueller Kurs
$123.06
Sicherheitsmarge
-23.3%
Innerer-Wert-Spanne
$64.86 - $134.71
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
293.43
ROE
15.4%
P/B-Verhältnis
18.88
P/FCF
124.60
Bruttomarge
98.3%
ROIC
0.7%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
0.7%
WACC
8.0%
ROIC − WACC
-7.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (15)
- EPS shows upward trend
- Price CAGR 32.63%
- Gross Margin 98.3%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 8.4%
- Revenue Growth 5Y 16.6%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 1684.0%
- Earnings Quality (OCF/NI) 1.99
Nicht bestanden (9)
- ROIC 0.7%
- P/FCF 124.60
- P/B Ratio 18.88
- Operating Margin 0.8%
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 5.9%
- Net Margin Trend 6.6% vs 18.7%
- Piotroski F-Score 4/9
Nicht verfügbar (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 68 |
| Mr. Atabak Mokari | CFO & Treasurer | 48 |
| Mr. Sean Maduck | President of Endocrinology | 48 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 57 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 62 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 47 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 65 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | - |
| Ms. Monica Tellado | President of Emerging Markets | 52 |
| Mr. Roberto W. Vieira | President of Oncology | - |
Prüfungsrisiko
8
Vorstandsrisiko
5
Vergütungsrisiko
7
Aktionärsrechterisiko
7
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for CORT, sourced from Markets Gazette.